AllianceBernstein’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

AllianceBernstein’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-51,500	Closed	-$197K	–	3273
2020 Q1	$197K	Buy	51,500 +5,800	+13%	+$26.9K	﹤0.01%	2808
2019 Q4	$276K	Hold	45,700	–	–	﹤0.01%	2809
2019 Q3	$345K	Hold	45,700	–	–	﹤0.01%	2741
2019 Q2	$619K	Buy	+45,700	New	+$528K	﹤0.01%	2513
2018 Q2	–	Sell	-21,100	Closed	-$183K	–	3154
2018 Q1	$183K	Hold	21,100	–	–	﹤0.01%	2873
2017 Q4	$264K	Buy	+21,100	New	+$242K	﹤0.01%	2769

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

PCM

Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AllianceBernstein's ZYNE Position: Q2 2020 in Review

AllianceBernstein sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2020, closing a stake of 51,500 shares — an estimated $197K sold.

AllianceBernstein first reported a position in ZYNE in Q4 2017 and held it in 6 quarters. The position peaked at $619K in Q2 2019. 74 funds tracked by Wall St. Rank hold ZYNE as of Q2 2020.

AllianceBernstein reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2020 after selling out during the quarter.
AllianceBernstein sold 51,500 Zynerba Pharmaceuticals, Inc shares in Q2 2020, an estimated $197K.
AllianceBernstein first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2017 and held it in 6 quarters.
AllianceBernstein's Zynerba Pharmaceuticals, Inc position peaked at $619K in Q2 2019.
74 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2020.

Based on AllianceBernstein's 13F filing for Q2 2020, filed 13 Aug 2020.